[Abstracts]
[How to Contact Us]
 

Newsletter 2014

It is with saddened hearts that we report the sudden unexpected passing of our beloved founder and director, Dr. Joseph Gold, M.D. on March 1, 20l4. We, at the Syracuse Cancer Research Institute, are committed to carrying on his healing work that is benefiting cancer patients throughout the world. The following is a brief ‘bio’ of the highlights of Dr. Gold’s remarkable career:

After graduation from Upstate NY Medical School at Syracuse, Dr. Gold was awarded a US Public Health Fellowship at the University of California at Berkeley, where his continuous interest in carbohydrate metabolism found expression. He synthesized via a one-step inorganic synthesis a research biochemical—until then unavailable. This carbohydrate intermediate, synthesized by Dr. Gold, was central to many energy reactions in the body and thus became available for worldwide research.

As a Research Medical Officer in the US Air Force, Dr. Gold played a principal role in the Mercury Astronaut Selection Program. Dr. Gold won recognition as an outstanding exponent in the field of heat stress, publishing a lead article in the Journal of the American Medical Association on the mechanism of heat stroke, which became adapted in the newly published textbooks on internal medicine. For his work in heat physiology, crucial to our space program, Dr. Gold received a citation of recognition from President Dwight D. Eisenhower.

Returning to his Alma Mater at Upstate Medical Center in Syracuse, as a Research Fellow, then as Assistant Professor of Pharmacology and Pathology, Dr. Gold engaged in research on the use of human tissues as a means of a new methodology in cancer research. In testing tumor tissue obtained directly from the operating room, Dr. Gold found that surrounding tissue, that looked normal (morphologically normal) was indeed biochemically ‘cancerous.’ He called these ‘transitional cells’, a discovery and a naming validated within the last l0 years by a respected Texas researcher.

Dr. Gold soon turned his attention to the problem of cancer cachexia. Cancer Cachexia is the condition of progressive bodily debilitation and weight loss, thought to be responsible for two-thirds of cancer deaths. Until Dr. Gold’s original work, cancer cachexia was but a descriptive term. In 1968 Dr. Gold published a paper (Proposed Treatment of Cancer by Inhibition of Gluconeogenesis, Oncology 22: l85-207) describing the actual biochemical mechanisms responsible for cancer cachexia.

A high rate of gluconeogenesis is commonly found in cancer patients. Dr. Gold proposed that inhibition of gluconeogenesis at a certain enzyme level could constitute an effective inhibition of cancer cachexia with attendant cancer treatment benefits. Research at the University of Wisconsin Enzyme Institute later showed the common chemical hydrazine sulfate as both an inhibitor of cancer cachexia and tumor growth. Six years of preclinical studies firmly established hydrazine sulfate as an inhibitor of cancer cachexia and tumor growth. Controlled clinical trials followed: 10 years of Phase III randomized placebo controlled, double blind trials at Harbor-UCLA Cancer Center in Torrance, CA and 17 years of multi-center Phase II trials, headquartered at the N.N. Petrov Research Institute of Oncology in St. Petersburg, Russia. These studies disclosed the following: A 50% measurable symptomatic improvement response, 40% tumor regression of stabilization for at least 3 months, 5% to 10% long-terms (greater than 10 years) survival, called “complete response”. All studies were published in premier American peer reviewed journals.

Despite these remarkable result using hydrazine sulfate in the treatment of cancer, the National Cancer Institute continued its long standing opposition to hydrazine sulfate and its developer, Dr. Joseph Gold. At this point, it is important to know that hydrazine sulfate was recognized as a MAO inhibitor. Drugs known as MAOIs should not be used with psycho-active drugs and certain foods high in tyramine. Around 1990 the National Cancer Institute sponsored studies including several lung cancer studies. However, after being forewarned by respected scientists and others, the NCI proceeded to mix hydrazine sulfate, a documented MAO inhibitor , with tranquilizers, psycho-active drugs. Tranquilizers, incompatible with hydrazine sulfate, were used as ‘anti-nausea’ drugs in the NCI’s ‘negative’ studies. Steroids, compatible with hydrazine sulfate , were used, when needed, in all the positive studies. In addition, ZOFRAN, an anti-nausea drug compatible with hydrazine sulfate was granted a United States Use Patent in 1988.

Thus, for whatever motives, the NCI declared hydrazine sulfate ‘worthless’. For a background of these events please visit: “The Truth About Hydrazine Sulfate—Dr. Gold Speaks” (www.hydrazinesulfate.org). In an August 1, 2013 paper there is corroboration between the positive Harbor UCLA and Petrov Oncology Institute studies. Added to these positive studies are the newly positive clinical results to date of SEHYDRIN, trade name of hydrazine sulfate, produced by the pharmaceutical company called PHARMSYNTHEZ in Russia.

Pharmsynthez states: SEHYDRIN’s (HYDRAZINE SULFATE’s) therapeutic effects are: “increased appetite and weight, decreased spitting of blood and respiratory insufficiency (in lung cancer patients), decreased edema and effusions (fluid accumulation), improved overall health, easing of depression…a feeling of well being…elimination of pain (allowing the reduction or discontinuation of pain medications)…a statistically significant increase in duration of remission in breast cancer, brain tumors, lung cancer.” In addition, a Ukrainian pharmaceutical business called GFMG, based in Kiev, states on its website: “SEHYDRIN (HYDRAZINE SULFATE) improves life quality UNPRECEDENTEDLY in even the most terminal patient. Controlled positive clinical trials, both Russian and American, were performed in accordance with the multi-nationally ratified Helsinki Declaration. The Helsinki Declaration is a set of principles governing safe and allowable procedures in the conduct of human biomedical studies so that no harm results. Principle l states: “Biomedical research involving human beings must conform to generally accepted scientific principles and be based on a thorough knowledge of the scientific literature.” The positive hydrazine sulfate studies, both Russian and American, used compatible agents with hydrazine sulfate—steroids as anti-nausea drugs, as needed.

The large NCI studies were negative, violating the tenets of Principle 1 of the Helsinki Declaration. “…use of incompatible medication (tranquilizers with a MAO inhibitor) is known to result in a negative clinical study as well as represent a ‘clinical hazard’…” Violation of the Helsinki Declaration is unknown in international drug testing!

In short, after being forewarned by prominent scientists about the potentially lethal mixture of psychoactive drugs and MAO inhibitors— After being presented with animal data demonstrating such toxicity— After being aware of the safe use of steroids as anti-nausea drugs in the previous positive Russian and American studies— After possibly being aware of the emergence of Ondansetron (ZOFRAN), as a safe anti-nausea drug— The National Cancer Institute chose to us tranquilizers as their anti-nausea drugs—a known incompatible with hydrazine sulfate.

A highly respected attorney, formerly associated with Congress declared: The NCI studies are “meaningless.” Perhaps true; but the political ramifications were destructive, particularly to the cancer patient. In light of these sobering facts, the personal question arises: What would you do if you or someone you cared for got a diagnosis of cancer?

To paraphrase an unfaltering guideline:

‘You shall know the truth and the truth shall make you free…’ to make critical choices.

Despite obstacles, the Syracuse Cancer Research Institute has become the life saving beacon for cancer patients the world over. Our Global Outreach Program has become a life line for patients, their doctors, their families and care givers who reach out for help in the many languages of the world. Today cancer is a pandemic.

Hydrazine sulfate can help. Sometimes in combination with other modalities, with chemotherapy, with radiation. Sometimes as a sole agent.

Syracuse Cancer Research is a life line to those afflicted with cancer. And it is your donations that keep this life line going.

Without your help, we cannot help you. Or others. In today’s economy money is often short. But time is also short for many cancer patients.

Keep Syracuse Cancer Research Institute strong and viable.

Please give what you can.

Sincerely, Judith Taylor, Associate Director

Joseph Gold, M.D.

 


This page is designed and hosted by Next Generation Computer Systems, and is the property of the Syracuse Cancer Research Institute. © 1996, Syracuse Cancer Research Institute. All rights reserved.
Last modified on 04 June 1998 by
webteam@ngen.com.